Nivolumab plus docetaxel versus placebo plus docetaxel for androgen receptor pathway inhibitor-pretreated and chemotherapy-naive metastatic castration-resistant prostate cancer (CheckMate 7DX): a double-blind, randomised, phase 3 trial.

Date publication

janvier 2026

Journal

The Lancet. Oncology

Auteurs

Membres identifiés du Cancéropôle Est :
Dr BARTHELEMY Philippe

Tous les auteurs :
Fizazi K, Saad F, Alonso-Gordoa T, Żurawski B, Barthélémy P, Voog E, Javier Cutuli H, Buchler T, Ye D, Castellano D, Kwiatkowski M, Arslan C, Richardet M, Alifrangis C, Goh JC, Vianna K, Han W, Hatano K, Todenhöfer T, Retz M, Srivastava A, Jin C, Gupta S, Trandafirescu G, Campos A, Lee CW, van Kooten Losio M, Subudhi SK

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/41449150

Résumé

Androgen receptor pathway inhibitors (ARPIs) and docetaxel are established standards of care for chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC). We aimed to assess the efficacy and safety of adding nivolumab to docetaxel versus docetaxel alone in ARPI-pretreated, chemotherapy-naive mCRPC.

Mots clés

Humans, Male, Docetaxel, administration & dosage, Nivolumab, administration & dosage, Prostatic Neoplasms, Castration-Resistant, drug therapy, Double-Blind Method, Aged, Antineoplastic Combined Chemotherapy Protocols, therapeutic use, Middle Aged, Aged, 80 and over, Progression-Free Survival, Receptors, Androgen, metabolism, Androgen Receptor Antagonists, administration & dosage, Adult

Référence

Lancet Oncol. 2026 01;27(1):68-78